NHS watchdogs will review decision not to fund Alzheimer's drugs lecanemab and donanemab after appeal by manufacturers. The National Institute for Health and Care Excellence (NICE) has confirmed the review under new cost-effectiveness thresholds agreed in the US trade deal. The drugs are intended for mild cognitive impairment or mild dementia caused by Alzheimer's disease. NICE has previously found they are not cost-effective, with treatment costing five to six times more than the usual threshold. They include the high cost of regular infusions and monitoring for side effects such as swelling and bleeding in the brain.[1][2][6]